Cagrilintide
Long-acting amylin analog — the other half of CagriSema's ~22.7% Phase 3 weight loss
At a glance
What it is: Long-acting amylin analog — the other half of CagriSema's ~22.7% Phase 3 weight loss.
Primary research applications:
- Weight management (as part of CagriSema combination therapy)
- Investigational obesity + type 2 diabetes treatment
- Glycemic control via glucagon suppression
Editorial summary: Cagrilintide is not the next semaglutide — it is something different and potentially more important. Its mechanism targets the amylin pathway, entirely distinct from the GLP-1 axis. Combined with semaglutide in the REDEFINE Phase 3 program, CagriSema produced approximately 22.7% mean weight loss at 68 weeks — outperforming semaglutide alone and approaching tirzepatide-tier efficacy. The compound is not FDA-approved.
What is Cagrilintide?
Cagrilintide is a synthetic, long-acting analog of amylin — a 37-amino acid peptide hormone co-secreted with insulin by pancreatic beta cells whenever blood glucose rises after a meal. In people with type 2 diabetes and many people with obesity, amylin secretion is blunted, which may contribute to impaired satiety signaling.[1]
Native amylin has a plasma half-life measured in minutes, making it impractical as a therapeutic. Novo Nordisk's medicinal chemistry team solved this through fatty-acid acylation and amino-acid substitutions that extend the half-life enough to allow once-weekly subcutaneous injection — the same dosing convenience as semaglutide.
On its own, cagrilintide produces modest weight loss (Phase 2 monotherapy: ~6–10% at 26 weeks). Novo Nordisk's strategy was never to develop it as a standalone drug. The goal was always combination: pairing cagrilintide's amylin-axis satiety signal with semaglutide's GLP-1-axis signal in a single weekly injection. That combination is called CagriSema.
As of June 2026, cagrilintide is not FDA-approved in any form and cannot be prescribed in the United States outside of a clinical trial.
Mechanism of action
Satiety is not a single signal — it is a convergence of multiple hormonal inputs arriving at the brainstem and hypothalamus. Most obesity pharmacology of the past decade has targeted one axis: GLP-1. Semaglutide and tirzepatide (which also hits GIP receptors) both work primarily through this pathway.
Amylin acts on a completely different set of receptors — primarily the amylin receptor complex (a heterodimer of calcitonin receptor and receptor activity-modifying proteins, primarily RAMP1 and RAMP3), expressed in the area postrema and nucleus tractus solitarius (brainstem regions that integrate meal-size and gastric-stretch signals). It also signals through calcitonin receptors. The downstream effects:
- Central appetite suppression via brainstem-to-hypothalamus projections — pathways that do not overlap significantly with GLP-1R signaling.
- Slowing of gastric emptying via vagal inhibition — food stays in the stomach longer, prolonging fullness.
- Post-prandial glucagon suppression — reducing hepatic glucose output and hyperglycemic spikes after meals.
- Reduced food reward signaling — preclinical data suggest amylin agonism blunts the palatability-driven "wanting more" signal even when satiated.
The amylin and GLP-1 pathways converge at the level of energy homeostasis but use different receptors and partially different neural circuits. Blocking one does not abolish the other. This is why the combination produces additive — not merely incremental — weight loss.
What the research shows
The peer-reviewed literature on Cagrilintide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| CagriSema produces ~22.7% weight loss at 68 weeks | REDEFINE 1 Phase 3 primary endpoint | Supported |
| Amylin and GLP-1 mechanisms are additive, not redundant | Phase 1b and Phase 3 data both confirm combination beats either alone | Supported |
| Reduces food intake through a non-GLP-1 mechanism | Mechanism well-established; amylin receptor pharmacology confirmed | Supported |
| Suppresses post-prandial glucagon | Phase 1b and mechanistic studies | Supported |
| Slows gastric emptying | Pharmacodynamic studies | Supported |
| Cagrilintide is a powerful weight-loss drug on its own | Phase 2 monotherapy ~10% at 26 weeks — useful but not class-leading | Mixed |
| CagriSema is approved and available | Not approved; Phase 3 complete but NDA not yet filed as of June 2026 | Unsupported |
| Will definitively replace tirzepatide as the leading agent | Efficacy numbers comparable; head-to-head trials have not been run | Uncertain |
Reported user experiences
How the research describes administration
Administered once weekly by subcutaneous injection in trials, with stepwise titration. Not approved for clinical use as of 2026.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Cagrilintide is more interesting as a combination partner (CagriSema) than as a standalone. The mechanism is complementary to GLP-1, but the incremental benefit over semaglutide or tirzepatide monotherapy is still being defined by Phase 3 data.
Frequently asked questions
Is cagrilintide a peptide?
Yes — cagrilintide is a 37-amino-acid peptide, an analog of amylin (not GLP-1). See Are GLP-1 medications peptides? for how it fits into the broader peptide-drug class.
What is cagrilintide's brand name?
It does not have one yet. Cagrilintide is investigational — not approved as a standalone drug. Its primary clinical development is as part of CagriSema, the co-formulated combination with semaglutide that is in Phase 3 trials (the REDEFINE program). If CagriSema is approved, it will be the first commercial product containing cagrilintide.
What is amylin and why target it?
Amylin is a 37-amino acid hormone co-secreted with insulin from pancreatic beta cells. It signals satiety through brainstem pathways separate from GLP-1. Targeting both systems simultaneously produces additive effects on food intake.
Is cagrilintide the same as pramlintide?
Both are amylin analogs, but pramlintide (Symlin) is a short-acting version approved for diabetes that requires multiple daily injections. Cagrilintide is engineered for once-weekly use.
Is cagrilintide available?
Not as an approved drug. Its primary clinical role is expected to be as part of CagriSema, which is still in late-stage development. See our CagriSema Phase 3 coverage for the latest timeline.
How much weight loss does cagrilintide produce alone?
Approximately 6–10% at 26 weeks in Phase 2 — roughly comparable to first-generation GLP-1 agonists, but below the newer incretin class.
References
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64:11183-11194. https://pubmed.ncbi.nlm.nih.gov/34320805/
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398:2160-2172. https://pubmed.ncbi.nlm.nih.gov/34774493/
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. Lancet. 2021;397:1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/